Terence Flynn
Stock Analyst at Morgan Stanley
(4.16)
# 367
Out of 4,826 analysts
187
Total ratings
58.59%
Success rate
9.4%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OGN Organon & Co. | Maintains: Equal-Weight | $15 → $10 | $8.90 | +12.42% | 10 | May 5, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $346 → $348 | $294.69 | +18.09% | 9 | May 1, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $241 → $250 | $197.01 | +26.90% | 16 | Apr 28, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $164 → $169 | $154.86 | +9.13% | 21 | Apr 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,146 → $1,124 | $829.60 | +35.49% | 19 | Apr 9, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $328 → $330 | $279.36 | +18.13% | 6 | Apr 9, 2025 | |
| ARVN Arvinas | Maintains: Equal-Weight | $48 → $12 | $7.60 | +57.89% | 8 | Mar 13, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $145 → $139 | $101.18 | +37.38% | 2 | Mar 11, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $69 → $63 | $22.74 | +177.04% | 2 | Mar 7, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $36 → $25 | $8.87 | +181.85% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $37.81 | -15.37% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $113 → $106 | $82.60 | +28.33% | 16 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $11.01 | +54.41% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $8.56 | +28.50% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $39 | $50.05 | -22.08% | 10 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $31 | $24.08 | +28.74% | 17 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $26.29 | +348.84% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $4.28 | +741.12% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $51 | $32.70 | +55.96% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $101.83 | +64.99% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $1.63 | +390.80% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $123.28 | +253.67% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $268.72 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.32 | - | 1 | Jul 21, 2017 |
Organon & Co.
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $8.90
Upside: +12.42%
United Therapeutics
May 1, 2025
Maintains: Equal-Weight
Price Target: $346 → $348
Current: $294.69
Upside: +18.09%
AbbVie
Apr 28, 2025
Maintains: Overweight
Price Target: $241 → $250
Current: $197.01
Upside: +26.90%
Johnson & Johnson
Apr 16, 2025
Maintains: Equal-Weight
Price Target: $164 → $169
Current: $154.86
Upside: +9.13%
Eli Lilly and Company
Apr 9, 2025
Maintains: Overweight
Price Target: $1,146 → $1,124
Current: $829.60
Upside: +35.49%
Amgen
Apr 9, 2025
Maintains: Equal-Weight
Price Target: $328 → $330
Current: $279.36
Upside: +18.13%
Arvinas
Mar 13, 2025
Maintains: Equal-Weight
Price Target: $48 → $12
Current: $7.60
Upside: +57.89%
BioNTech SE
Mar 11, 2025
Maintains: Overweight
Price Target: $145 → $139
Current: $101.18
Upside: +37.38%
Biohaven
Mar 7, 2025
Maintains: Overweight
Price Target: $69 → $63
Current: $22.74
Upside: +177.04%
Arcus Biosciences
Feb 18, 2025
Maintains: Overweight
Price Target: $36 → $25
Current: $8.87
Upside: +181.85%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $37.81
Upside: -15.37%
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $113 → $106
Current: $82.60
Upside: +28.33%
Feb 3, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $11.01
Upside: +54.41%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $8.56
Upside: +28.50%
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $50.05
Upside: -22.08%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $30 → $31
Current: $24.08
Upside: +28.74%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $26.29
Upside: +348.84%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $4.28
Upside: +741.12%
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $32.70
Upside: +55.96%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $101.83
Upside: +64.99%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $1.63
Upside: +390.80%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $123.28
Upside: +253.67%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $268.72
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.32
Upside: -